Who
Sravan Kumar Emany
Director
Company insider
Files Form 4 as: Director, Assertio Holdings; Chief Financial Officer, Beam Therapeutics; Director, Kyverna Therapeutics; SVP, COO and CFO, Ironwood Pharmaceuticals.
In numbers
- Trades disclosed
- 43
- Buys
- 2
- Sells
- 3
- Bought
- $400K
- Sold
- $462K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 6 Dec 2021
- Last trade
- 16 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 16 Jun 2026 | Assertio HoldingsBiotechnology | SEC FORM 4 Code U | —23,855 at $0.00 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,753 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative | SEC FORM 4 Code D | —1,753 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdings | SEC FORM 4 Code U | —23,855 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | Assertio HoldingsBiotechnology | SEC FORM 4 Code A | —4,851 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | Assertio Holdings | SEC FORM 4 Code A | —4,851 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —31,750 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —31,750 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,006 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,945 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,945 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,006 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —63,500 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —63,500 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $171K6,294 at $27.10 | filing |
| 31 Dec 2025filed 5 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $171K6,294 at $27.10 | filing |
News
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?BEAM · fool.com · 18 Oct 2026Beam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exerciseBEAM · tickerreport.com · 17 Oct 2026Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressBEAM · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Sravan Kumar Emany; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.